In osteosarcoma, Prkci promoted cell growth via the Akt/mTOR pathway, while in pancreatic cancer, Prkci and RIPK2 jointly enhanced NF-κB/JNK/ERK signaling, driving cancer cell proliferation and invasion[10,13,14]. Here, RIPK2 is linked to cancer.